Download PDF
Zahnmedizin up2date 2017; 11(01): 23-37
DOI: 10.1055/s-0042-113040
Oralmedizin
Georg Thieme Verlag KG Stuttgart · New York

Antiresorptiva-assoziierte Kiefernekrosen

Tim F. Wolff
,
Knut A. Grötz
Further Information

Publication History

Publication Date:
01 March 2017 (online)

Also available at
    Permissions and Reprints All articles of this category
Fazit

Die Antiresorptiva-assoziierte Kiefernekrose stellt sowohl für den Zahnarzt, den Oralchirurgen als auch für den Mund-, Kiefer- und Gesichtschirurgen eine Herausforderung in der Prophylaxe und Früherkennung dar. Durch konsequente prophylaktische Maßnahmen lässt sich die Prävalenz der ONJ senken. Wohingegen früher eine antiresorptive Therapie als Kontraindikation für eine Implantation angesehen wurde, zeigen neuere Studien und Erkenntnisse, dass die Risikoevaluation im Vordergrund steht. Bei Einhaltung bestimmter Sicherheitskautelen ist eine Implantation auch bei Hochrisikopatienten möglich.

 

  • Literatur

  • 1 Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117
    CrossrefPubMedGoogle Scholar
  • 2 Grötz KA. Risikopatienten in der ZMK (inkl. Impl. bei Risikopatienten). In: Grötz KA. Hrsg. Handbuch ZMK 2015: ZMK-Update 2015. Wiesbaden: Med Publico; 2015
    Google Scholar
  • 3 von Moos R. Bisphosphonate treatment recommendations for oncologists. Oncologist 2005; 10 (Suppl. 01) 19-24
    CrossrefPubMedGoogle Scholar
  • 4 Arantes HP, Silva AG, Lazaretti-Castro M. Bisphosphonates in the treatment of metabolic bone diseases. Arq Bras Endocrinol Metabol 2010; 54: 206-212
    CrossrefPubMedGoogle Scholar
  • 5 Tsao C, Darby I, Ebeling PR. et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013; 71: 1360-1366
    CrossrefPubMedGoogle Scholar
  • 6 Pushalkar S, Li X, Kurago Z. et al. Oral microbiota and host innate immune response in bisphosphonate-related osteonecrosis of the jaw. Int J Oral Sci 2014; 6: 219-226
    CrossrefPubMedGoogle Scholar
  • 7 Thumbigere-Math V, Michalowicz BS, Hodges JS. et al. Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw. J Periodontol 2014; 85: 226-233
    CrossrefPubMedGoogle Scholar
  • 8 Walter C, Laux C, Sagheb K. Radiologic bone loss in patients with bisphosphonate-associated osteonecrosis of the jaws: a case-control study. Clin Oral Investig 2014; 18: 385-390
    CrossrefPubMedGoogle Scholar
  • 9 Ruggiero SL, Mehrotra B, Rosenberg TJ. et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534
    CrossrefPubMedGoogle Scholar
  • 10 Ruggiero SL, Dodson TB, Assael LA. et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. J Oral Maxillofac Surg 2009; 67 (05) Suppl 2-12
    CrossrefPubMedGoogle Scholar
  • 11 Groetz KA, Piesold JU, Al-Nawas B. S3-Leitlinie: Bisphosphonat-assoziierte Kiefernekrose (BP-ONJ) und andere Medikamenten-assoziierte Kiefernekrosen. AWMF 007–091, 2012. Im Internet: http://www.awmf.org/leitlinien/detail/II/007-091.html Stand: 22.01.2017
    Google Scholar
  • 12 Smith MR, Saad F, Coleman R. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379 (9810) 39-46
    CrossrefPubMedGoogle Scholar
  • 13 Groetz KA. Onko II: Supportive TU-Betreuung. In: Groetz KA, Hassfeld S, Schmidt-Westhausen AM. Hrsg. Handbuch MKG 2016: MKG-Update 2016. Wiesbaden: Med Publico; 2016
    Google Scholar
  • 14 Guarneri V, Miles D, Robert N. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010; 122: 181-188
    CrossrefPubMedGoogle Scholar
  • 15 Christodoulou C, Pervena A, Klouvas G. et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009; 76: 209-211
    CrossrefPubMedGoogle Scholar
  • 16 zm-online. Rote-Hand-Brief für Zaltrap. 07/2016. Im Internet: http://www.zm-online.de/hefte/Rote-Hand-Brief-fuer-Zaltrap_344687.html Stand: 01.06.2016
    Google Scholar
  • 17 Pilanci KN, Alco G, Ordu C. et al. Is administration of trastuzumab an independent risk factor for developing osteonecrosis of the jaw among metastatic breast cancer patients under zoledronic acid treatment?. Medicine (Baltimore) 2015; 94: e671
    CrossrefPubMedGoogle Scholar
  • 18 Ponzetti A, Pinta F, Spadi R. et al. Jaw osteonecrosis associated with aflibercept, irinotecan and fluorouracil: attention to oral district. Tumori 2016; DOI: 10.5301/tj.5000405.
    CrossrefPubMedGoogle Scholar
  • 19 Grötz KA, Al-Nawas B. Persisting alveolar sockets – a radiologic symptom of BP-ONJ?. J Oral Maxillofac Surg 2006; 64: 1571-1572
    PubMedGoogle Scholar
  • 20 Grötz KA. Patientenbezogener Laufzettel „Überweisung/Konsil vor Bisphosphonat-Therapie“, ASORS Arbeitsgemeinschaft Supportive Maßnahmen in der Onkologie, Rehabilitation und Sozialmedizin der Deutschen Krebsgesellschaft, Stand 06/2012. Im Internet: http://www.onkosupport.de/asors/content/e4126/e1743/e1861/e1862 Stand: 15.07.2016
    Google Scholar
  • 21 Sim Ie W, Sanders KM, Borromeo GL. et al. Declining Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Cancer. J Clin Endocrinol Metab 2015; 100: 3887-3893
    CrossrefPubMedGoogle Scholar
  • 22 Bramati A, Girelli S, Farina G. et al. Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. J Bone Miner Metab 2015; 33: 119-124
    CrossrefPubMedGoogle Scholar
  • 23 Vandone AM, Donadio M, Mozzati M. et al. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. Ann Oncol 2012; 23: 193-200
    CrossrefPubMedGoogle Scholar
  • 24 Montefusco V, Gay F, Spina F. et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008; 49: 2156-2162
    CrossrefPubMedGoogle Scholar
  • 25 Krimmel M, Ripperger J, Hairass M. et al. Does dental and oral health influence the development and course of bisphosphonate-related osteonecrosis of the jaws (BRONJ)?. Oral Maxillofac Surg 2014; 18: 213-218
    CrossrefPubMedGoogle Scholar
  • 26 Walter C, Al-Nawas B, Frickhofen N. et al. Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients. Head Face Med 2010; 6: 11
    CrossrefPubMedGoogle Scholar
  • 27 Treister N, Sheehy N, Bae EH. et al. Dental panoramic radiographic evaluation in bisphosphonate-associated osteonecrosis of the jaws. Oral Dis 2009; 15: 88-92
    CrossrefPubMedGoogle Scholar
  • 28 Stockmann P, Hinkmann FM, Lell MM. et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Investig 2010; 14: 311-317
    CrossrefPubMedGoogle Scholar
  • 29 Hoff AO, Toth BB, Altundag K. et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-836
    CrossrefPubMedGoogle Scholar
  • 30 Van den Wyngaert T, Claeys T, Huizing MT. et al. Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome. Ann Oncol 2009; 20: 331-336
    PubMedGoogle Scholar
  • 31 Lazarovici TS, Yahalom R, Taicher S. et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009; 67: 850-855
    CrossrefPubMedGoogle Scholar
  • 32 Stockmann P, Vairaktaris E, Wehrhan F. et al. Osteotomy and primary wound closure in bisphosphonate-associated osteonecrosis of the jaw: a prospective clinical study with 12 months follow-up. Support Care Cancer 2010; 18: 449-460
    CrossrefPubMedGoogle Scholar
  • 33 Wilde F, Heufelder M, Winter K. et al. The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011; 111: 153-163
    CrossrefPubMedGoogle Scholar
  • 34 Vescovi P, Manfredi M, Merigo E. et al. Surgical approach with Er : YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers Med Sci 2010; 25: 101-113
    CrossrefPubMedGoogle Scholar
  • 35 Pautke C, Bauer F, Bissinger O. et al. Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy. J Oral Maxillofac Surg 2010; 68: 125-129
    CrossrefPubMedGoogle Scholar
  • 36 Longo F, Guida A, Aversa C. et al. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: personal experience and review of the literature. Int J Dent 2014; 2014: 298945
    PubMedGoogle Scholar
  • 37 Norholt SE, Hartlev J. Surgical treatment of osteonecrosis of the jaw with the use of platelet-rich fibrin: a prospective study of 15 patients. Int J Oral Maxillofac Surg 2016; 45: 1256-1260
    CrossrefPubMedGoogle Scholar
  • 38 Groetz KA, Al-Nawas B. Laufzettel Biophosphonate Risiko-Evaluation bei antiresorptiver Therapie vor Implantation, 2013. Im Internet: http://www.dginet.de/web/dgi/laufzettel-bisphosphonate Stand: 15.07.2016
    Google Scholar
  • 39 Kumar MN, Honne T. Survival of dental implants in bisphosphonate users versus non-users: a systematic review. Eur J Prosthodont Restor Dent 2012; 20: 159-162
    PubMedGoogle Scholar
  • 40 Kasai T, Pogrel MA, Hossaini M. The prognosis for dental implants placed in patients taking oral bisphosphonates. J Calif Dent Assoc 2009; 37: 39-42
    PubMedGoogle Scholar
  • 41 Siebert T, Jurkovic R, Statelova D, Strecha J. Immediate Implant Placement in a Patient With Osteoporosis Undergoing Bisphosphonate Therapy: 1-Year Preliminary Prospective Study. J Oral Implantol 2015; 41 Spec No: 360-365
    CrossrefPubMedGoogle Scholar
  • 42 Lazarovici TS, Yahalom R, Taicher S. et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010; 68: 790-796
    CrossrefPubMedGoogle Scholar
  • 43 Shabestari GO, Shayesteh YS, Khojasteh A. et al. Implant Placement in Patients with Oral Bisphosphonate Therapy: A Case Series. Clin Implant Dent Relat Res 2010; 12: 175-180
    PubMedGoogle Scholar
  • 44 Kwon TG, Lee CO, Park JW. et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014; 25: 632-640
    PubMedGoogle Scholar
  • 45 Buttchereit I, Scholz M, Frerich B. et al. . Periimplantoplastik bei Bisphosphonaten. Zahnärztliche Mitteilungen 2015; 8: 44-48
    Google Scholar
  • 46 Walter C, Al-Nawas B, Wolff T. et al. Dental implants in patients treated with antiresorptive medication – a systematic literature review. Int J Implant Dent 2016; 2: 9
    CrossrefPubMedGoogle Scholar